{
    "score": [
        0.6153846153846154
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "$ 13.20 million in sales expected for juniper pharmaceuticals inc this quarter ."
    ],
    "id": "1045000.train",
    "article": [
        "brokerages predict that juniper pharmaceuticals inc will post sales of $ 13.20 million for the current fiscal quarter , according to zacks . two analysts have issued estimates for juniper pharmaceuticals ' earnings . the highest sales estimate is $ 16.00 million and the lowest is $ 10.40 million . juniper pharmaceuticals reported sales of $ 20.93 million in the same quarter last year , which would suggest a negative year over year growth rate of 36.9 % . the business is expected to report its next quarterly earnings report on tuesday , march 6th . on average , analysts expect that juniper pharmaceuticals will report full year sales of $ 13.20 million for the current year , with estimates ranging from $ 48.59 million to $ 54.19 million . ",
        "for the next fiscal year , analysts anticipate that the business will report sales of $ 79.17 million per share , with estimates ranging from $ 56.80 million to $ 101.53 million . zacks investment research 's sales calculations are an average based on a survey of sell-side research firms that cover juniper pharmaceuticals . juniper pharmaceuticals last issued its earnings results on thursday , november 2nd . the specialty pharmaceutical company reported eps for the quarter , topping the consensus estimate of by $ 0.09 . juniper pharmaceuticals had a net margin of 10.80 % and a return on equity of 17.32 % . ",
        "several research firms have recently issued reports on jnp . valuengine downgraded juniper pharmaceuticals from a `` hold '' rating to a `` sell '' rating in a research note on friday , december 1st . roth capital began coverage on juniper pharmaceuticals in a research note on tuesday , january 2nd . they set a `` buy '' rating and a $ 12.00 price target for the company . finally , hc wainwright reaffirmed a `` neutral '' rating on shares of juniper pharmaceuticals in a research note on monday , november 6th . one investment analyst has rated the stock with a sell rating , one has given a hold rating and two have issued a buy rating to the company . ",
        "juniper pharmaceuticals has an average rating of `` hold '' and an average price target of $ 23.00 . juniper pharmaceuticals remained flat at $ $ 6.30 during trading hours on wednesday . the company 's stock had a trading volume of 21,142 shares , compared to its average volume of 39,180 . the firm has a market cap of $ 68.32 , a price-to-earnings ratio of 10.50 and a beta of 0.03 . the company has a current ratio of 2.00 , a quick ratio of 1.68 and a debt-to-equity ratio of 0.08 . juniper pharmaceuticals has a 1 year low of $ 3.65 and a 1 year high of $ 6.40 . ",
        "large investors have recently added to or reduced their stakes in the company . goldman sachs group inc. . raised its stake in shares of juniper pharmaceuticals by 3.4 % during the 2nd quarter . goldman sachs group inc. . now owns 21,735 shares of the specialty pharmaceutical company 's stock worth $ 110,000 after buying an additional 715 shares during the last quarter . macquarie group ltd. . acquired a new position in shares of juniper pharmaceuticals during the 3rd quarter worth $ 129,000 . nationwide fund advisors raised its stake in shares of juniper pharmaceuticals by 5,500.0 % during the 2nd quarter . ",
        "nationwide fund advisors now owns 56,000 shares of the specialty pharmaceutical company 's stock worth $ 283,000 after buying an additional 55,000 shares during the last quarter . dimensional fund advisors lp raised its stake in shares of juniper pharmaceuticals by 1.9 % during the 2nd quarter . dimensional fund advisors lp now owns 72,875 shares of the specialty pharmaceutical company 's stock worth $ 368,000 after buying an additional 1,344 shares during the last quarter . finally , algert global llc raised its stake in shares of juniper pharmaceuticals by 20.4 % during the 3rd quarter . algert global llc now owns 144,565 shares of the specialty pharmaceutical company 's stock worth $ 658,000 after buying an additional 24,530 shares during the last quarter . ",
        "36.39 % of the stock is owned by institutional investors and hedge funds . copyright violation notice : this story was originally posted by american banking news and is owned by of american banking news . if you are accessing this story on another site , it was stolen and republished in violation of u. s. & international copyright legislation . the legal version of this story can be read at pharmaceuticals company profilejuniper pharmaceuticals , inc is a women 's health therapeutics company . the company is focused on developing therapeutics that address unmet medical needs in women 's health . ",
        "it operates in two segments : product and service . the product segment is engaged in manufacturing and supplying crinone , the company 's commercialized product . get a free copy of the zacks research report on juniper pharmaceuticals for more information about research offerings from zacks investment research , visit zacks . comreceive news & ratings for juniper pharmaceuticals daily - enter your email address below to receive a concise daily summary of the latest news and analysts ' ratings for juniper pharmaceuticals and related companies with marketbeat . com 's free daily email newsletter .   "
    ]
}